However, each medicine comes with its own pros and cons based on your medical history and the drugs you are already taking
Side effect risks are higher when you first start Ozempic and when you raise your dose
4.Chichura, K.S., Elfers, C.T., Salameh, T.S
Simultaneous start protocol (standard approach) When to use: Starting both peptides fresh (no prior use) Following clinical trial model exactly Want maximum proven efficacy Can tolerate both from beginning Week-by-week dosing schedule: Weeks 1-4: Semaglutide: 0.25mg weekly Cagrilintide: 0.6mg weekly Inject same day OR different days (preference) Separate injection sites if same day Tips: Start ginger supplementation, small meals, hydrate well Weeks 5-8: Semaglutide: 0.5mg weekly (2x increase) Cagrilintide: 1.2mg weekly (2x increase) Nausea typically increases this phase Tips: Anti-nausea meds ready, protein shakes if needed, slow eating Weeks 9-12: Semaglutide: 1.0mg weekly Cagrilintide: 1.8mg weekly Peak side effect window Tips: May need to extend by 1-2 weeks if struggling, Zofran helpful Weeks 13-16: Semaglutide: 1.7mg weekly Cagrilintide: 2.4mg weekly (cagrilintide at target) Semaglutide still escalating Tips: Cagrilintide side effects should be stabilizing Week 17+: Semaglutide: 2.4mg weekly (both at maximum) Cagrilintide: 2.4mg weekly Maintenance dosing Continue indefinitely Tips: Side effects typically moderate by now (adapted) Injection logistics: Both subcutaneous injections Can inject same day (different sites: left/right abdomen) OR split: Semaglutide Monday, Cagrilintide Thursday Rotate sites to prevent irritation 29-31 gauge insulin syringes See our peptide injections guide , how to reconstitute peptides , and peptide dosing guide
Nootropics Depot advertises the product as being effective for "cellular support, metabolic function, and cognition," none of which are typically associated with silymarin
Background and FDAs Announcement FDA's April 1, 2026, update to its compounding policy page follows more than 18 months of regulatory activity surrounding the compounding of GLP-1 medications, primarily semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound)
